
Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.9%, driven by a pullback from EirGenix of 5.5%. On the other hand Locus Cell is actually up 21%. The industry has fallen 5.6% in the last year.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 26 May 2026 | NT$33.3b | NT$2.7b | -NT$746,869,000.00 | 20.8x | -44.6x | 12.6x |
| Thu, 23 Apr 2026 | NT$37.2b | NT$2.5b | -NT$767,980,000.00 | 22.3x | -48.4x | 14.9x |
| Sat, 21 Mar 2026 | NT$31.4b | NT$2.5b | -NT$747,966,000.00 | 20.6x | -41.9x | 12.5x |
| Mon, 16 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.8x | -48.3x | 13.7x |
| Wed, 14 Jan 2026 | NT$34.4b | NT$2.4b | -NT$689,929,000.00 | 25x | -49.9x | 14.2x |
| Fri, 12 Dec 2025 | NT$37.7b | NT$2.4b | -NT$670,921,000.00 | 20.7x | -56.2x | 15.4x |
| Sun, 09 Nov 2025 | NT$35.3b | NT$2.5b | -NT$870,437,000.00 | 17.4x | -40.6x | 14.4x |
| Tue, 07 Oct 2025 | NT$38.3b | NT$2.5b | -NT$870,437,000.00 | 19.5x | -44.1x | 15.6x |
| Thu, 04 Sep 2025 | NT$34.9b | NT$2.5b | -NT$819,216,000.00 | 20.2x | -42.7x | 14.2x |
| Sat, 02 Aug 2025 | NT$33.4b | NT$2.5b | -NT$600,003,000.00 | 21.5x | -55.7x | 13.6x |
| Mon, 30 Jun 2025 | NT$33.5b | NT$2.5b | -NT$600,003,000.00 | 23.3x | -55.8x | 13.6x |
| Wed, 28 May 2025 | NT$31.4b | NT$2.5b | -NT$604,301,000.00 | 22.1x | -51.9x | 12.8x |
| Fri, 25 Apr 2025 | NT$31.1b | NT$2.5b | -NT$540,128,000.00 | 23.7x | -57.6x | 12.6x |
| Sun, 23 Mar 2025 | NT$36.6b | NT$2.4b | -NT$560,979,000.00 | 28.5x | -65.2x | 15.2x |
| Tue, 18 Feb 2025 | NT$37.4b | NT$2.6b | -NT$854,432,000.00 | 23.5x | -43.7x | 14.6x |
| Thu, 16 Jan 2025 | NT$36.5b | NT$2.6b | -NT$854,432,000.00 | 23x | -42.7x | 14.2x |
| Sat, 14 Dec 2024 | NT$33.7b | NT$2.6b | -NT$854,432,000.00 | 24.8x | -39.5x | 13.2x |
| Mon, 11 Nov 2024 | NT$42.0b | NT$2.5b | -NT$712,402,000.00 | 24x | -59x | 16.7x |
| Wed, 09 Oct 2024 | NT$41.7b | NT$2.3b | -NT$836,610,000.00 | 22.4x | -49.8x | 18.3x |
| Fri, 06 Sep 2024 | NT$40.1b | NT$2.3b | -NT$836,610,000.00 | 21.8x | -47.9x | 17.6x |
| Sun, 04 Aug 2024 | NT$41.5b | NT$2.1b | -NT$797,765,000.00 | 32x | -52x | 19.4x |
| Tue, 02 Jul 2024 | NT$46.0b | NT$2.1b | -NT$797,765,000.00 | 35.1x | -57.6x | 21.5x |
| Thu, 30 May 2024 | NT$40.7b | NT$2.1b | -NT$797,765,000.00 | 32.1x | -51.1x | 19.1x |
| Sat, 27 Apr 2024 | NT$39.4b | NT$2.1b | -NT$914,899,000.00 | 31.6x | -43.1x | 18.6x |
| Mon, 25 Mar 2024 | NT$40.2b | NT$2.1b | -NT$606,177,000.00 | 31.3x | -66.4x | 19.4x |
| Wed, 21 Feb 2024 | NT$44.3b | NT$2.1b | -NT$610,218,000.00 | 33x | -72.5x | 21.3x |
| Fri, 19 Jan 2024 | NT$44.5b | NT$2.1b | -NT$610,218,000.00 | 32.8x | -73x | 21.5x |
| Sun, 17 Dec 2023 | NT$48.6b | NT$2.1b | -NT$610,218,000.00 | 32.8x | -79.7x | 23.4x |
| Tue, 14 Nov 2023 | NT$48.1b | NT$2.2b | -NT$497,769,000.00 | 31.6x | -96.7x | 21.6x |
| Thu, 12 Oct 2023 | NT$48.1b | NT$2.2b | -NT$497,769,000.00 | 31.1x | -96.6x | 21.6x |
| Sat, 09 Sep 2023 | NT$43.1b | NT$2.2b | -NT$497,769,000.00 | 31.3x | -86.5x | 19.4x |
| Mon, 07 Aug 2023 | NT$47.1b | NT$2.4b | -NT$281,587,000.00 | 44.7x | -167.4x | 19.3x |
| Wed, 05 Jul 2023 | NT$49.1b | NT$2.5b | -NT$274,767,000.00 | 43.1x | -178.7x | 20x |
| Fri, 02 Jun 2023 | NT$50.1b | NT$2.5b | -NT$262,467,000.00 | 43.9x | -190.9x | 20.2x |
-190.9x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 6.63% | |
| Healthcare | 1.85% | |
| Life Sciences | 3.29% | |
| Clinical Research and Equipment | 3.29% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6891 Locus Cell | NT$57.30 | 15.4% +NT$1.5b | 160.5% | PS899.9x | |
| 6848 RBC Bioscience | NT$19.50 | 1.6% +NT$3.9m | 15.3% | PE10.7x | |
| 6661 Welgene BiotechLtd | NT$17.60 | 0.9% +NT$3.5m | -18.9% | PS1.1x |